FindTrial
Sign In

Insuline resistance treatment effect in patients with genotype 1 hepatitis C treated with peginterferon alfa-2a plus ribavirin in usual clinical practice Efecto del tratamiento de la resistencia a insulina en los pacientes con hepatitis C crónica genotipo 1 tratados con peginterferón alfa-2a en combinación con ribavirina en la práctica clínica habitual - Insuline resistance treatment effect in genotype 1 hepatitis C treated with Peg-IFN alfa 2a & RBV

Insuline resistance treatment effect in patients with genotype 1 hepatitis C treated with peginterferon alfa-2a plus ribavirin in usual clinical practice Efecto del tratamiento de la resistencia a insulina en los pacientes con hepatitis C crónica genotipo 1 tratados con peginterferón alfa-2a en combinación con ribavirina en la práctica clínica habitual - Insuline resistance treatment effect in genotype 1 hepatitis C treated with Peg-IFN alfa 2a & RBV

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-002446-19-ES
Enrollment
Unknown
Registered
2005-07-27
Start date
2005-09-10
Completion date
Unknown
Last updated
2012-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment effect of insuline resistance in patients with genotype 1 hepatitis C treated with peginterferon alfa 2a plus ribavirin in usual clinical practice

Interventions

Trade Name: Pegasys 180 mcg Product Name: peginterferon alfa 2a Product Code: peginterferon alfa 2a Pharmaceutical Form: Suspension for injection INN or Proposed INN: PEGINTERFERON ALFA 2A Concentrati

Sponsors

Hospital de Valme
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: Resistance insuline treatment effect on the svr 24 weeks after stopping 48 weeks with peginterferon alfa 2a plus ribavirin;Secondary Objective: Effectiveness and security of metformine to stop the insuline resistance in genotype 1 hepatitis C patients;Primary end point(s):—

Countries

Spain

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026